Navigation Links
Transition in cell type parallels treatment response, disease progression in breast cancer
Date:1/31/2013

A process that normally occurs in developing embryos the changing of one basic cell type into another has also been suspected of playing a role in cancer metastasis. Now a study from Massachusetts General Hospital (MGH) Cancer Center researchers has associated this process, called epithelial-mesenchymal transition or EMT, with disease progression and treatment response in breast cancer patients. The report also identifies underlying mechanisms that someday may become therapeutic targets.

"Until now, EMT had only been modeled in experimental systems, but its clinical relevance was uncertain. Now we show that it can be detected in samples from breast cancer patients and that the tumor cells oscillate between these two states" says Shyamala Maheswaran, PhD, of the MGH Cancer Center, co-corresponding author of the report in the Feb. 1 issue of Science. "We find that the EMT state of breast cancer cells evolves in response to therapy and to disease recurrence, pointing to involvement of this mechanism in tumor spread and invasiveness."

Epithelial tissues line most bodily surfaces and cavities, and epithelial cells closely adhere to each other. During development, some epithelial cells develop traits of mesenchymal cells, including the ability to migrate to other parts of the embryo, establish themselves and develop into organs or other types of tissue. Several studies have suggested that a transition from epithelial to mesenchymal cell type is also involved with cancer metastasis, which involves tumor cells' migration to and invasion of other sites in the body, but identifying EMT stages of tissues has been challenging.

The MGH investigators developed a new assay that determines EMT stage by screening tumor samples for seven epithelial markers and three mesenchymal markers. In primary tumor samples from several breast cancer patients including samples of estrogen-receptor/progesterone-receptor-positive, HER2-positive
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Topological transitions in metamaterials
2. Study Shows Transition to Practice Programs Get Nurses Employed
3. Innosight Announces Leadership Transition
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
6. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
7. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
8. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
9. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
10. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
11. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... , ... The next-generation sequencing (NGS) clinical market is poised for huge growth ... BCC Research reveals in its new report that the market drivers of this vibrant ... need for better diagnostics as part of a molecular diagnostics trend. , The global ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, ... has earned three Gold, three Silver, and three Bronze ... gala held in Chicago this ... the premier business awards program in the U.S. ... our company,s strength in developing leaders, cultivating talent, creating ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 ... CTI’ new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous ... control device that will increase healthcare worker safety and reduce financial costs. , ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
...  Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences ... analysis of a Phase 2 study of quizartinib (formerly ... the 53rd Annual Meeting of the American Society of ... presented from two additional posters: one evaluating the pharmacodynamic ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced the ... a disease gene in an adult mouse model of hemophilia ... the 53nd Annual Meeting of the American Society of Hematology ... human gene for the clotting factor, Factor IX, with a ...
... animal cells is usually achieved through the accumulation of glucose, ... glycogen. But when this accumulation happens in neurons it is ... associated with glycogen accumulation is the hallmark of an extremely ... (LD). The journal EMBO Molecular Medicine ...
Cached Biology Technology:Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 2Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 5Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 6Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 7Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 8Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting 2Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting 3Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting 4A mouse model brings new perspectives on Lafora disease 2
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... two-year study of the potential health effects associated with ... Gulf War. , The study, "An Analysis of Uranium ... Study," performed by Sandia scientist Al Marshall, employs analytical ... examines health risks associated with uranium handling. , U.S. ...
... today announced the receipt of a $7.1 million grant ... a project designed to uncover the genetic causes of ... technologies. This award is part of a greater $25 ... microarray centers that are part of the NIH Neuroscience ...
... Health Network and University of Toronto have identified a ... patient with chronic Hepatitis C will be able to ... become the basis of a simple new test in ... therapy. , The study, published in the May issue ...
Cached Biology News:Sandia completes depleted uranium study 2TGen awarded $7.1 million to accelerate brain disease research 2Identification of specific genes predicts which patients will respond to Hepatitis C treatment 2Identification of specific genes predicts which patients will respond to Hepatitis C treatment 3
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
... a recombinant Moloney murine leukemia virus ... is similar to MuLV reverse transcriptase ... MuLV reverse transcriptase is a recombinant ... RNA as a template in the ...
Biology Products: